Naveen Pemmaraju

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Naval Daver, Guillermo Garcia‐Manero, Sreyashi Basu et al. · Cancer Discovery · 2018 · 559 citations

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 491 citations · Full text

Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

Courtney D. DiNardo, Caitlin R. Rausch, Christopher B. Benton et al. · American Journal of Hematology · 2017 · 429 citations · Full text

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri et al. · Blood · 2018 · 394 citations · Full text

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 335 citations · Full text

Hematological Malignancy, Oncology, Biochemistry +8